

Self-Injection Device Market Set to Reach \$10.31B by 2031, Driven by Homecare Demand | DataM Intelligence

Explore the booming self-injection device market driven by chronic disease management, tech innovation, and rising demand for home-based healthcare solutions.

AUSTIN, TX, UNITED STATES, May 29, 2025 /EINPresswire.com/ -- The [Self-Injection Device Market](#) was valued at USD 4.31 billion in 2023 and is projected to reach USD 10.31 billion by 2031, growing at a CAGR of 13.3% from 2024 to 2031.

The global self-injection device market is undergoing rapid transformation, fueled by a rising demand for patient-centric drug delivery solutions. Self-injection devices empower patients to administer medications themselves, improving compliance, reducing the need for hospital visits, and enhancing overall healthcare efficiency. These devices are particularly crucial for managing chronic conditions such as diabetes, rheumatoid arthritis, multiple sclerosis, and hormone disorders conditions that require regular dosing over long periods.

“The self-injection device market is set to grow from \$4.31B in 2023 to \$10.31B by 2031, driven by tech innovation, chronic disease rise, and demand for home-based care.”

DataM Intelligence

diseases



Download Exclusive Sample Report Here:
<https://www.datamintelligence.com/download-sample/self-injection-device-market>

This significant growth trajectory is being driven by multiple factors:

A growing global aging population prone to chronic

Advances in biologics that require regular injectable administration

Increasing focus on healthcare cost reduction

Rising awareness about home-based care and patient convenience

Technological innovations such as smart injectors, wearable devices, and needle-free technologies are further fueling adoption by improving safety, ease of use, and reducing needle anxiety.

Regional Outlook

North America

North America holds a dominant share in the self-injection device market. This is due to a well-established healthcare infrastructure, early adoption of advanced medical technologies, and a high burden of chronic diseases. Additionally, favorable reimbursement policies and increasing patient preference for at-home treatment contribute to market expansion. The U.S., in particular, continues to lead the region due to regulatory support and active participation from both pharmaceutical and medtech companies.

Europe

Europe is also a significant contributor, with countries such as Germany, the UK, and France showing robust growth. Initiatives promoting digital healthcare and homecare therapies, coupled with a rising geriatric population, are key drivers in the region. Moreover, awareness campaigns on chronic disease management and government efforts to promote self-care practices are boosting market potential.

Asia-Pacific

The Asia-Pacific region is emerging as a fast-growing market, led by countries like China, Japan, India, and South Korea. Increasing healthcare investments, rising healthcare literacy, and the growing prevalence of diabetes and autoimmune diseases are primary growth factors.

Key Companies in the Market

Becton

Dickinson and Company

Ypsomed AG

Fresenius Kabi

Gerresheimer AG

Pfizer Inc

Antares Pharma, Inc

West Pharmaceutical Services

Insulet Corporation

Owen Mumford Ltd

SHL Group Auto.

Latest News from the USA

In a notable development in April 2025, the U.S. Food and Drug Administration (FDA) approved a prefilled syringe version of Vyvgart, a breakthrough therapy from Argenx. This self-injection format allows patients suffering from generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) to administer the drug in the comfort of their homes. This shift significantly reduces patient dependency on infusion centers and hospitals, making treatment more accessible and less time-consuming.

This approval marks a broader trend in the U.S. healthcare system to promote home-based therapies. With chronic diseases placing long-term pressure on healthcare infrastructure, self-injection devices are being embraced as both cost-effective and patient-friendly solutions. Furthermore, telemedicine services are increasingly being integrated with self-injection therapies, enabling real-time guidance and remote monitoring.

Latest News from Japan

Japan, known for its aging population and strong pharmaceutical innovation, is also witnessing major strides in the self-injection space. In September 2024, SHL Medical entered into a strategic collaboration with FUJIFILM Diosynth Biotechnologies to enhance final assembly capabilities for SHL's widely used Molly® autoinjector. This partnership aims to improve manufacturing agility and expand the availability of autoinjectors tailored to complex biologic formulations.

This collaboration reflects Japan's national push to localize manufacturing and bolster healthcare automation. With a high proportion of elderly citizens and a cultural preference for precision and reliability, Japanese consumers are particularly receptive to advanced drug delivery systems. Companies in Japan are also focused on developing intuitive designs that require minimal patient training—an essential factor in the market's expansion.

Market Segmentation:

By Product: Pen Injectors, Wearable Injectors, Needle-Free Injectors, Autoinjectors.

By Usage: Disposable, Reusable.

By Application: Autoimmune Disorder, Allergic Disorders, Hormonal Disease, Infectious Diseases, Other.

By Distribution Channels: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

By Region: North America, Europe, South America, Asia Pacific, Middle East, and Africa.

Conclusion

The self-injection device market is poised for robust and sustained growth in the coming years. With patients increasingly seeking autonomy and comfort in managing chronic diseases, and healthcare systems pushing for cost-effective, home-based solutions, these devices are becoming integral to modern medicine.

Technological advancements are removing long-standing barriers such as needle phobia and dosing complexity. Meanwhile, market leaders continue to innovate and scale globally, while regional players focus on affordability and ease-of-use. With the U.S. embracing connected care models and Japan advancing manufacturing and R&D efforts, the future of self-injection devices is both promising and patient-centered.

Stay informed with the latest industry insights-start your subscription now:

<https://www.datamintelligence.com/reports-subscription>

Related Reports:

[Drug Delivery Infusion System Market](#)

[Nasal Drug Delivery Systems Market](#)

Sai Kumar

DataM Intelligence 4market Research LLP

+1 877-441-4866

[email us here](#)

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/817160831>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.